PL212096B1 - Wyizolowane szczepy Bifidobacterium infantis i środek farmaceutyczny - Google Patents

Wyizolowane szczepy Bifidobacterium infantis i środek farmaceutyczny

Info

Publication number
PL212096B1
PL212096B1 PL378435A PL37843504A PL212096B1 PL 212096 B1 PL212096 B1 PL 212096B1 PL 378435 A PL378435 A PL 378435A PL 37843504 A PL37843504 A PL 37843504A PL 212096 B1 PL212096 B1 PL 212096B1
Authority
PL
Poland
Prior art keywords
cure
strains
bifidobacterium
glutamine
bifidobacterium infantis
Prior art date
Application number
PL378435A
Other languages
English (en)
Polish (pl)
Other versions
PL378435A1 (pl
Inventor
Göran Molin
Siv Ahrné
Bengt Jeppsson
Original Assignee
Probi Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probi Ab filed Critical Probi Ab
Publication of PL378435A1 publication Critical patent/PL378435A1/pl
Publication of PL212096B1 publication Critical patent/PL212096B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/529—Infantis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
PL378435A 2003-01-31 2004-01-27 Wyizolowane szczepy Bifidobacterium infantis i środek farmaceutyczny PL212096B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0300245A SE526711C2 (sv) 2003-01-31 2003-01-31 Nya stammar av Bifidobacterium med förmåga att överleva i magtarmkanalen och producera glutamin in vivo, samt kompositioner och användningar därav
US44727403P 2003-02-14 2003-02-14

Publications (2)

Publication Number Publication Date
PL378435A1 PL378435A1 (pl) 2006-04-03
PL212096B1 true PL212096B1 (pl) 2012-08-31

Family

ID=20290264

Family Applications (1)

Application Number Title Priority Date Filing Date
PL378435A PL212096B1 (pl) 2003-01-31 2004-01-27 Wyizolowane szczepy Bifidobacterium infantis i środek farmaceutyczny

Country Status (16)

Country Link
US (1) US7947482B2 (enExample)
EP (1) EP1587913B1 (enExample)
JP (1) JP4540664B2 (enExample)
CN (1) CN100558883C (enExample)
AT (1) ATE496115T1 (enExample)
AU (1) AU2004208084B2 (enExample)
BR (1) BRPI0407176B8 (enExample)
CA (1) CA2514659C (enExample)
DE (1) DE602004031079D1 (enExample)
DK (1) DK1587913T3 (enExample)
ES (1) ES2362496T3 (enExample)
PL (1) PL212096B1 (enExample)
RU (1) RU2352628C2 (enExample)
SE (1) SE526711C2 (enExample)
WO (1) WO2004067731A1 (enExample)
ZA (1) ZA200505777B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11045507B2 (en) 2019-02-21 2021-06-29 Ewelina Sosnowska-Turek Bifidobacterium animalis AMT30 strain and the composition containing the strain of Bifidobacterium animalis AMT30

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5363811B2 (ja) 2005-09-28 2013-12-11 ノルディスク リバランス アクティーゼルスカブ 治療エフェクターとしてプロバイオティック細菌と発酵穀物を用いるｉｂｄ及びｉｂｓの治療
EP1951273B1 (en) * 2005-10-06 2014-02-12 Probi Ab Use of lactobacillus for treatment of autoimmune diseases
WO2012005240A1 (ja) * 2010-07-05 2012-01-12 株式会社明治 腸内腐敗物質の低減作用を有するビフィズス菌
CL2010001124A1 (es) 2010-10-14 2011-01-21 Univ De Concepcion 50% Ma Loreto Ormeno 50% Alimento funcional probiotico que comprende cepas viables de lactobacillus sp.; uso de dicho alimento funcional para contrarestar los efectos colaterales de la quimioterapia.
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
CN103131647B (zh) * 2011-11-29 2017-06-27 上海上药信谊药厂有限公司 婴儿双歧杆菌及其制剂
IN2014DN07752A (enExample) 2012-02-29 2015-05-15 Ethicon Endo Surgery Inc
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
SG10201903823QA (en) 2014-10-31 2019-05-30 Whole Biome Inc Methods and compositions relating to microbial treatment and diagnosis of disorders
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
CN108330166A (zh) * 2017-09-06 2018-07-27 深圳市百澳飞生物技术有限公司 一种酶制剂的饲用活性评估方法
CN113164526A (zh) 2018-07-19 2021-07-23 潘德勒姆治疗公司 用于微生物植入的方法和组合物
RU2699967C1 (ru) * 2018-12-25 2019-09-11 Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) Способ комплексного лечения энтеральной недостаточности у детей с тяжелой термической травмой

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59155321A (ja) * 1983-02-25 1984-09-04 Riyoushiyoku Kenkyukai 整腸用製剤
DE3406772A1 (de) * 1984-02-24 1986-03-13 Angelo 8137 Berg Schuler Diaetetisches mittel zur herabsetzung der harnstoffkonzentration in koerperfluessigkeiten und seine herstellung
SE9002732D0 (sv) * 1990-08-24 1990-08-24 Kabivitrum Ab Product containing growth factor
IT1254210B (it) 1992-02-10 1995-09-14 Simone Claudio De Composizioni dietetiche e/o farmaceutiche a base di batteri lattici liofilizzati, loro preparazione e impiego
JP3623977B2 (ja) * 1993-10-29 2005-02-23 明治乳業株式会社 潰瘍性大腸炎治療剤
JP4852681B2 (ja) * 1996-02-28 2012-01-11 雪印メグミルク株式会社 腸管内細胞溶解活性抑制剤
IT1288119B1 (it) * 1996-06-28 1998-09-10 Renata Maria Anna Ve Cavaliere Composizioni dietetiche da utilizzare nell'alimentazione per via enterica
RU2112034C1 (ru) * 1996-12-26 1998-05-27 Московский научно-исследовательский институт эпидемиологии и микробиологии им.Г.Н.Габричевского Штамм bifidobacterium infantis 73-15, используемый для приготовления бифидосодержащих бактерийных препаратов и продуктов лечебно-диетического питания
US6203797B1 (en) * 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
ID29150A (id) * 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
US6468525B1 (en) * 1999-08-10 2002-10-22 Renew Life, Inc. Probiotic formulation
CA2407724A1 (en) 2000-05-03 2001-11-08 University Of Maryland, Baltimore Oral gram(+) bacteria and glutamine composition for prevention and/or treatment of gastro-intestinal
WO2002003879A1 (en) * 2000-07-07 2002-01-17 First Circle Medical, Inc. Treatment of hiv using hyperthermia
JP2002186422A (ja) * 2000-12-22 2002-07-02 Morinaga Milk Ind Co Ltd ラクトバシラス・ガッセリ及びビフィドバクテリウム属の菌を含有する非発酵食品
FI109602B (fi) 2001-01-25 2002-09-13 Valio Oy Probioottiyhdistelmä
US7550285B2 (en) * 2001-02-06 2009-06-23 Nestec S.A. Endotoxin binding lactic acid bacteria and bifidobacteria
US20030017192A1 (en) * 2001-06-19 2003-01-23 Hanny Kanafani Process for producing extended shelf-life ready-to-use milk compositions containing probiotics
US20030092163A1 (en) * 2001-07-26 2003-05-15 Collins John Kevin Probiotic bifidobacterium strains
JP3364491B2 (ja) * 2002-07-25 2003-01-08 株式会社アトリエ・ド・フロマージュ ヨーグルトおよびその製造方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11045507B2 (en) 2019-02-21 2021-06-29 Ewelina Sosnowska-Turek Bifidobacterium animalis AMT30 strain and the composition containing the strain of Bifidobacterium animalis AMT30

Also Published As

Publication number Publication date
ATE496115T1 (de) 2011-02-15
AU2004208084A1 (en) 2004-08-12
RU2352628C2 (ru) 2009-04-20
BRPI0407176B8 (pt) 2021-05-25
CN100558883C (zh) 2009-11-11
SE0300245L (sv) 2004-08-01
SE526711C2 (sv) 2005-10-25
CN1777670A (zh) 2006-05-24
US20060269533A1 (en) 2006-11-30
ZA200505777B (en) 2007-12-27
DE602004031079D1 (de) 2011-03-03
CA2514659A1 (en) 2004-08-12
ES2362496T3 (es) 2011-07-06
SE0300245D0 (sv) 2003-01-31
RU2005127331A (ru) 2006-01-27
BRPI0407176B1 (pt) 2018-05-08
EP1587913A1 (en) 2005-10-26
DK1587913T3 (da) 2011-04-11
EP1587913B1 (en) 2011-01-19
US7947482B2 (en) 2011-05-24
PL378435A1 (pl) 2006-04-03
JP4540664B2 (ja) 2010-09-08
CA2514659C (en) 2014-07-08
BRPI0407176A (pt) 2006-02-07
JP2006516405A (ja) 2006-07-06
AU2004208084B2 (en) 2008-10-09
WO2004067731A1 (en) 2004-08-12

Similar Documents

Publication Publication Date Title
ES2324532T3 (es) Bacteria probiotica: lactobacillus fermentum.
US10583158B2 (en) Compositions comprising bacterial strains
La Ragione et al. In vivo characterization of Lactobacillus johnsonii FI9785 for use as a defined competitive exclusion agent against bacterial pathogens in poultry
US10155015B2 (en) Probiotic compositions for use in the treatment of bowel diseases
Saulnier et al. Microbiology of the human intestinal tract and approaches for its dietary modulation
US9839657B2 (en) Prebiotic compositions comprising one or more types of bacteriophage
JP4011532B2 (ja) ビフィズス菌およびそれを含有する製剤
EP2828375B1 (en) Gaba-producing culturable bacteria derived from the human gastrointestinal tract
TW201805011A (zh) 包含細菌菌株之組合物
JP2006522766A (ja) シンビオティックな組み合わせ
CN1568365A (zh) 包含戊糖乳杆菌菌株的组合物及其用途
CN112218646B (zh) 一种组合物及其应用
PL212096B1 (pl) Wyizolowane szczepy Bifidobacterium infantis i środek farmaceutyczny
CN116396884A (zh) 鼠李糖乳杆菌和一种抑制幽门螺杆菌的组合物
US11224620B2 (en) Compositions comprising bacterial strains
RU2724585C2 (ru) Пробиотическая композиция для восстановления микрофлоры кишечника и для профилактики синдрома избыточного бактериального роста и диарей и способ ее получения
Beccati Investigations of prebiotics and of inter-and intra-molecular glycan-protein interactions
KR20230053941A (ko) 정자 기능 개선용 조성물 및 이의 용도
RU2491332C1 (ru) Консорциум бифидобактерий для приготовления бактерийных препаратов и биологически активных добавок к пище, предназначенных для коррекции микрофлоры желудочно-кишечного тракта людей старше 14 лет, и способ его получения, биологически активная добавка к пище для коррекции микрофлоры желудочно-кишечного тракта людей старше 14 лет и бактериальный препарат для лечения дисбиотических состояний желудочно-кишечного тракта людей старше 14 лет
Korzenik The Potential Impact of Probiotics and Prebiotics on Gastrointestinal and Immune Health of Combat Soldiers

Legal Events

Date Code Title Description
RECP Rectifications of patent specification